Novavax Inc. closed 69.07% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

After dropping by 15.74% to close at $1,707.94 yesterday, the stock could continue to pull back today. Shares fell after ...

The FDA has granted limited approval for Novavax’s COVID-19 vaccine, raising questions about access and population ...

This was the stock's second consecutive day of losses.

The FDA has granted full approval for Novavax's COVID-19 vaccine, but with restrictions. Discover the details now.

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization.